Northern India Herald

Birch Allergy Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies – Allergy Therapeutics Plc, Regeneron Pharma Inc., Desentum

 Breaking News
  • No posts were found

Birch Allergy Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies – Allergy Therapeutics Plc, Regeneron Pharma Inc., Desentum

April 25
15:21 2023
Birch Allergy Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight |  Key Companies - Allergy Therapeutics Plc, Regeneron Pharma Inc., Desentum
DelveInsight’s “Birch Allergy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Birch Allergy.

DelveInsight’s “Birch Allergy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Birch Allergy, historical and forecasted epidemiology as well as the Birch Allergy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Birch Allergy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Birch Allergy Market Forecast

 

Some of the key facts of the Birch Allergy Market Report: 

  • The Birch Allergy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • As per a study conducted by “Biedermann et al. (2019) found that birch pollen sensitization ranged from 8% to 16% in the general population of Europe. The population of Japan might have similar rates of sensitization to birch and alder as those in Europe
  • According to the French company, DJO Global, the pooled prevalence estimates indicate that Birch Allergy affects 23% of adults aged 18-65 and 35% of people aged over 65 in France
  • According to the U.S. National Health and Nutrition Examination Survey 2005-2006, 16% of 8,086 participants 6 years or older with allergy had a specific immunoglobulin E (IgE) to birch, while 18% had a specific IgE to oak
  • Key Birch Allergy Companies: Allergy Therapeutics Plc, Regeneron Pharmaceuticals Inc., Desentum HAL Allergy Group,  Roxall Medizin GmbH, Worg Pharmaceuticals AG, S-TARget therapeutics GmbH, Adamis Pharmaceuticals Corporation, Merck KGaA, Stallergenes Greer plc, and others
  • Key Birch Allergy Therapies: REGN5713-5714- 5715, SQ tree SLIT-tablet, ILT-101, sublingual immunotherapy, and others
  • The Birch Allergy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Birch Allergy pipeline products will significantly revolutionize the Birch Allergy market dynamics.

 

Birch Allergy Overview

Allergy is a condition that occurs when the body (the immune system) overreacts to something in the environment (triggers). It is caused by allergens, which are usually harmless substances but trigger an allergic reaction in some people. When the symptoms occur in late summer or early fall, some people call it hay fever.

 

Get a Free sample for the Birch Allergy Market Report –

https://www.delveinsight.com/sample-request/birch-allergy-market

 

Birch Allergy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Birch Allergy Epidemiology Segmentation:

The Birch Allergy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Birch Allergy
  • Prevalent Cases of Birch Allergy by severity
  • Gender-specific Prevalence of Birch Allergy
  • Diagnosed Cases of Episodic and Chronic Birch Allergy

 

Download the report to understand which factors are driving Birch Allergy epidemiology trends @ Birch Allergy Epidemiology Forecast

 

Birch Allergy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Birch Allergy market or expected to get launched during the study period. The analysis covers Birch Allergy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Birch Allergy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Birch Allergy Therapies and Key Companies

  • REGN5713-5714- 5715: Regeneron Pharmaceuticals
  • SQ tree SLIT-tablet: ALK-Abelló A/S
  • ILT-101: Assistance Publique

 

Discover more about therapies set to grab major Birch Allergy market share @ Birch Allergy Treatment Market

 

Birch Allergy Market Drivers

  • Increasing prevalence of Birch Allergy
  • Expansion of health care system
  • Ongoing development of precision

 

Birch Allergy Market Barriers

  • Ineffectiveness/Failure of Treatment
  • Slow uptake of immunotherapy

 

Scope of the Birch Allergy Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Birch Allergy Companies: Allergy Therapeutics Plc, Regeneron Pharmaceuticals Inc., Desentum HAL Allergy Group,  Roxall Medizin GmbH, Worg Pharmaceuticals AG, S-TARget therapeutics GmbH, Adamis Pharmaceuticals Corporation, Merck KGaA, Stallergenes Greer plc, and others
  • Key Birch Allergy Therapies: REGN5713-5714- 5715, SQ tree SLIT-tablet, ILT-101 ,sublingual immunotherapy, and others
  • Birch Allergy Therapeutic Assessment: Birch Allergy current marketed and Birch Allergy emerging therapies
  • Birch Allergy Market Dynamics: Birch Allergy market drivers and Birch Allergy market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Birch Allergy Unmet Needs, KOL’s views, Analyst’s views, Birch Allergy Market Access and Reimbursement 

 

To know more about Birch Allergy companies working in the treatment market, visit @ Birch Allergy Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Birch Allergy Market Report Introduction

2. Executive Summary for Birch Allergy

3. SWOT analysis of Birch Allergy

4. Birch Allergy Patient Share (%) Overview at a Glance

5. Birch Allergy Market Overview at a Glance

6. Birch Allergy Disease Background and Overview

7. Birch Allergy Epidemiology and Patient Population

8. Country-Specific Patient Population of Birch Allergy 

9. Birch Allergy Current Treatment and Medical Practices

10. Birch Allergy Unmet Needs

11. Birch Allergy Emerging Therapies

12. Birch Allergy Market Outlook

13. Country-Wise Birch Allergy Market Analysis (2019–2032)

14. Birch Allergy Market Access and Reimbursement of Therapies

15. Birch Allergy Market Drivers

16. Birch Allergy Market Barriers

17.  Birch Allergy Appendix

18. Birch Allergy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services